moxifloxacin has been researched along with Sensitivity and Specificity in 46 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (4.35) | 18.2507 |
| 2000's | 26 (56.52) | 29.6817 |
| 2010's | 17 (36.96) | 24.3611 |
| 2020's | 1 (2.17) | 2.80 |
| Authors | Studies |
|---|---|
| Alami, A; Bjerre, LM; Gravel, CA; Krewski, D; Mattison, D; Momoli, F; Taher, MK; Tsui, D | 1 |
| Ando, K; Cao, X; Izumi-Nakaseko, H; Matsukura, S; Naito, AT; Nakamura, Y; Sugiyama, A; Wada, T | 1 |
| Berg, A; Hanna, D; Hermann, D; Jamei, M; Patel, N; Polak, S; Romero, K | 1 |
| Chen, J; Dang, Q; Huang, DP; Tsong, Y | 1 |
| Jithavech, P; Kiatkumjorn, T; Na Bhuket, PR; Rojsitthisak, P; Thanawattanawanich, P; Wichitnithad, W | 1 |
| Helmy, SA | 1 |
| Choi, YJ; Jung, HC; Kim, JM; Kim, JS; Kim, N; Lee, JW; Nam, RH; Park, JH | 1 |
| de Droogh, E; Groenen, G; Mathys, V; Soetaert, K; van de Vyvere, M | 1 |
| Alam, SM; Alothman, ZA; Alqadami, AA; Naushad, M; Siddiqui, MR; Wabaidur, SM | 1 |
| Denis, E; Duvauchelle, T; Maison-Blanche, P; Robert, P; Shah, RR | 1 |
| Mullangi, R; Narasu, L; Shankar, BP; Srinivas, N | 1 |
| Goudah, A | 1 |
| Ciric, A; Djurdjevic, A; Djurdjevic, P; Stankov, MJ | 1 |
| De Jode, P; Fassi, B; Kabbaj, M; Tyl, B; Wheeler, W | 1 |
| Bergman, AJ; Bloomfield, DM; Ghosh, K; Gottesdiener, KM; Gutierrez, MJ; Herman, GA; Hickey, L; Hreniuk, D; Krishna, R; Miller, J; Stoltz, R; Wagner, JA | 1 |
| Chan, RC; Chang, KC; Yew, WW | 1 |
| Andreu, I; Aranda, A; Ariza, A; Blanca-Lopez, N; Doña, I; Mayorga, C; Rosado, A; Torres, MJ | 1 |
| Davis, LT; Fiscella, RG; Glickman, RD; Kumar, N; Nijm, LM; Peterson, RJ; Tu, EY; Ulanski, LJ | 1 |
| Li, D; Li, YZ; Liu, XY; Lu, J; Xu, YH | 1 |
| Alffenaar, JW; Brouwers, JR; Koster, RA; Uges, DR; Vu, DH | 1 |
| Kumar, AK; Ramachandran, G; Srinivasan, R; Sudha, V | 1 |
| Banerjee, SK; Borkar, RM; Padiya, R; Raju, B; Ramesh, M; Srinivas, R | 1 |
| Farina, C; Russello, G; Russo, A; Scaltrito, MM; Sisto, F | 1 |
| Cassone, M; Monaco, M; Pompeo, ME; Tarasi, A; Tarasi, D; Venditti, M | 1 |
| Bishai, WR; Chaisson, RE; Grosset, JH; Nuermberger, EL; O'Brien, RJ; Tyagi, S; Vernon, AN; Yoshimatsu, T | 1 |
| Garrison, MW; Madaras-Kelly, KJ; Schimmels, JA | 1 |
| Braga, PC; Culici, M; Dal Sasso, M; Ricci, D | 1 |
| Choo, CM; Lim, T; Lim, YS; Ngan, CC; Toh, GL | 1 |
| Bittner, T; Brade, V; Cinatl, J; Hunfeld, KP; Rödel, R | 1 |
| Bishai, WR; Chaisson, RE; Grosset, JH; Nuermberger, EL; O'Brien, RJ; Rosenthal, I; Tyagi, S; Vernon, AA; Williams, K; Yoshimatsu, T | 1 |
| Dionisio, D; Fabbri, C; Tortoli, E | 1 |
| Cardeñosa, O; Contreras-Rodríguez, A; Gutiérrez-Rubio, AT; Hernández-Oliva, GM; López-Merino, A; Migranas-Ortiz, R; Orrantia-Gradín, R | 1 |
| Cruz, LA; Hall, R | 1 |
| De Vecchi, E; Drago, L; Legnani, D; Nicola, L; Prenna, M; Ripa, S | 1 |
| Paramasivan, CN; Rahman, F; Sulochana, S | 1 |
| Allerberger, F; Cappellari, G; Cardaioli, C; Cavallaro, A; Fille, M; Miglioli, PA; Sossai, P | 1 |
| Ackermann, T; Bertram, N; Paar, WD; Sauerbruch, T; Schulte, S | 1 |
| Djurdjević, P; Jelikić-Stankov, M; Laban-Djurdjević, A | 1 |
| Ahmad, FJ; Chopra, S; Khar, RK; Motwani, SK | 1 |
| Ahmad, FJ; Chopra, S; Khar, RK; Kohli, K; Motwani, SK; Talegaonkar, S | 1 |
| Barrett, MS; Biedenbach, DJ; Croco, MA; Jones, RN | 1 |
| Blaschke, G; Heinig, R; Möller, JG; Stass, H | 1 |
| Breilh, D; Dubrez, J; Ducint, D; Jougon, J; Lemoine, T; Saux, MC; Velly, JF | 1 |
| Ahr, G; Andresen, P; Blaschke, G; Grünefeld, G; Möller, JG; Schierenberg, MO; Schulz, H; Soetebeer, UB | 1 |
| Georgopoulos, A; Graninger, W; Grisold, A; Mueller-Uri, P; Presterl, E | 1 |
| Gottlieb, T; Leroi, MJ; Siarakas, S | 1 |
1 review(s) available for moxifloxacin and Sensitivity and Specificity
| Article | Year |
|---|---|
Rapid assays for fluoroquinolone resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis.
Topics: Antitubercular Agents; Aza Compounds; Bacterial Proteins; DNA Gyrase; DNA, Bacterial; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Genotype; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Quinolines; Sensitivity and Specificity; Tuberculosis, Multidrug-Resistant | 2010 |
4 trial(s) available for moxifloxacin and Sensitivity and Specificity
| Article | Year |
|---|---|
Establishing assay sensitivity in QT studies: experience with the use of moxifloxacin in an early phase clinical pharmacology study and comparison with its effect in a thorough QT study.
Topics: Adolescent; Adult; Cost-Benefit Analysis; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Feasibility Studies; Fluoroquinolones; Humans; Long QT Syndrome; Male; Middle Aged; Moxifloxacin; Sensitivity and Specificity; Young Adult | 2015 |
Comparison of semiautomated and fully automated methods for QT measurement during a thorough QT/QTc study: variability and sample size considerations.
Topics: Adult; Aged; Aza Compounds; Cross-Over Studies; Diagnosis, Computer-Assisted; Double-Blind Method; Electrocardiography, Ambulatory; Female; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Quinolines; Sample Size; Sensitivity and Specificity; Young Adult | 2009 |
A thorough QTc study to assess the effect of sitagliptin, a DPP4 inhibitor, on ventricular repolarization in healthy subjects.
Topics: Adolescent; Adult; Aza Compounds; Cross-Over Studies; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Female; Fluoroquinolones; Humans; Male; Middle Aged; Models, Biological; Moxifloxacin; Pyrazines; Quinolines; Sensitivity and Specificity; Sitagliptin Phosphate; Time Factors; Triazoles; Young Adult | 2009 |
In vitro evaluation of IgE-mediated hypersensitivity reactions to quinolones.
Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Aza Compounds; Basophil Degranulation Test; Ciprofloxacin; Female; Fluoroquinolones; Humans; Hypersensitivity, Immediate; Immunologic Tests; Levofloxacin; Male; Middle Aged; Moxifloxacin; Ofloxacin; Quinolines; Quinolones; Radioimmunoassay; Sensitivity and Specificity; Young Adult | 2011 |
41 other study(ies) available for moxifloxacin and Sensitivity and Specificity
| Article | Year |
|---|---|
Systemic quinolones and risk of retinal detachment I: analysis of data from the US FDA adverse event reporting system.
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Anti-Bacterial Agents; Child; Child, Preschool; Female; Humans; Infant; Male; Middle Aged; Moxifloxacin; Pharmacoepidemiology; Pharmacovigilance; Quinolones; Retinal Detachment; Risk; Sensitivity and Specificity; United States; United States Food and Drug Administration; Young Adult | 2022 |
Sensitivity and Reliability of Halothane-anaesthetized Microminipigs to Assess Risk of Drug-induced Long QT Syndrome.
Topics: Anesthetics, Inhalation; Animals; Arrhythmias, Cardiac; Blood Pressure; Disease Models, Animal; Dose-Response Relationship, Drug; Fluoroquinolones; Halothane; Heart Rate; Long QT Syndrome; Male; Moxifloxacin; Reproducibility of Results; Risk Assessment; Sensitivity and Specificity; Swine; Swine, Miniature; Terfenadine | 2017 |
Quantitative approach for cardiac risk assessment and interpretation in tuberculosis drug development.
Topics: Adult; Algorithms; Antitubercular Agents; Cardiotoxicity; Diarylquinolines; Drug Development; Electrocardiography; Female; Heart; Humans; Male; Moxifloxacin; Risk Assessment; Sensitivity and Specificity; Torsades de Pointes; Tuberculosis | 2018 |
Assay sensitivity in "Hybrid thorough QT/QTc (TQT)" study.
Topics: Biological Assay; Control Groups; Cross-Over Studies; Dose-Response Relationship, Drug; Drugs, Investigational; Electrocardiography; Heart Rate; Humans; Linear Models; Long QT Syndrome; Moxifloxacin; Randomized Controlled Trials as Topic; Research Design; Sensitivity and Specificity | 2019 |
A simple and sensitive HPLC-fluorescence method for the determination of moxifloxacin in human plasma and its application in a pharmacokinetic study.
Topics: Administration, Oral; Anti-Bacterial Agents; Calibration; Chromatography, High Pressure Liquid; Female; Humans; Male; Moxifloxacin; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Fluorescence | 2018 |
Simultaneous quantification of linezolid, tinidazole, norfloxacin, moxifloxacin, levofloxacin, and gatifloxacin in human plasma for therapeutic drug monitoring and pharmacokinetic studies in human volunteers.
Topics: Acetamides; Adult; Anti-Infective Agents; Aza Compounds; Chromatography, High Pressure Liquid; Drug Monitoring; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Limit of Detection; Linezolid; Male; Moxifloxacin; Norfloxacin; Oxazolidinones; Quinolines; Reproducibility of Results; Sensitivity and Specificity; Tinidazole; Young Adult | 2013 |
GenoType HelicoDR test in the determination of antimicrobial resistance of Helicobacter pylori in Korea.
Topics: Aged; Anti-Bacterial Agents; Clarithromycin; DNA Gyrase; DNA Mutational Analysis; Drug Combinations; Drug Resistance, Bacterial; Female; Fluoroquinolones; Genotyping Techniques; Helicobacter Infections; Helicobacter pylori; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Point Mutation; Republic of Korea; RNA, Ribosomal, 23S; Sensitivity and Specificity | 2014 |
False-positive rifampicin resistance on Xpert® MTB/RIF caused by a silent mutation in the rpoB gene.
Topics: Aged; Amikacin; Amino Acid Sequence; Antibiotics, Antitubercular; Bacterial Proteins; DNA-Directed RNA Polymerases; Drug Resistance, Multiple, Bacterial; Ethambutol; Ethionamide; Fluoroquinolones; Genotype; Humans; Isoniazid; Male; Molecular Sequence Data; Moxifloxacin; Mutation; Mycobacterium tuberculosis; Phenotype; Pyrazinamide; Rifampin; Sensitivity and Specificity; Sputum; Tuberculosis, Pulmonary | 2014 |
Flow-injection chemiluminescence method for the determination of moxifloxacin in pharmaceutical tablets and human urine using silver nanoparticles sensitized calcein-KMnO4 system.
Topics: Anti-Bacterial Agents; Flow Injection Analysis; Fluoresceins; Fluoroquinolones; Glucosides; Humans; Luminescent Measurements; Manganese Compounds; Metal Nanoparticles; Moxifloxacin; Oxides; Reproducibility of Results; Sensitivity and Specificity; Silver; Tablets; Technology, Pharmaceutical; Urinalysis | 2015 |
Development and validation of a HPLC method for simultaneous quantitation of gatifloxacin, sparfloxacin and moxifloxacin using levofloxacin as internal standard in human plasma: application to a clinical pharmacokinetic study.
Topics: Administration, Oral; Analytic Sample Preparation Methods; Aza Compounds; Chromatography, High Pressure Liquid; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Male; Moxifloxacin; Ofloxacin; Quinolines; Reference Standards; Sensitivity and Specificity | 2008 |
Pharmacokinetics and tissue residues of moxifloxacin in broiler chickens.
Topics: Animals; Anti-Infective Agents; Aza Compounds; Chickens; Drug Residues; Fluoroquinolones; Half-Life; Kidney; Kinetics; Liver; Lung; Moxifloxacin; Muscle, Skeletal; Quinolines; Sensitivity and Specificity | 2009 |
Optimization of separation and determination of moxifloxacin and its related substances by RP-HPLC.
Topics: Anti-Bacterial Agents; Aza Compounds; Chromatography, High Pressure Liquid; Fluoroquinolones; Hydrogen-Ion Concentration; Moxifloxacin; Quinolines; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Spectrophotometry, Ultraviolet | 2009 |
An adaptable HPLC method for the analysis of frequently used antibiotics in ocular samples.
Topics: Acetamides; Animals; Anti-Bacterial Agents; Aza Compounds; Cefuroxime; Chromatography, High Pressure Liquid; Contact Lenses, Hydrophilic; Eye; Fluoroquinolones; Gatifloxacin; Linear Models; Linezolid; Moxifloxacin; Oxazolidinones; Quinolines; Rabbits; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Fluorescence; Vitreous Body | 2010 |
High performance liquid chromatography assay with ultraviolet detection for moxifloxacin: validation and application to a pharmacokinetic study in Chinese volunteers.
Topics: Adult; Aza Compounds; China; Chromatography, High Pressure Liquid; Drug Stability; Female; Fluoroquinolones; Humans; Least-Squares Analysis; Male; Moxifloxacin; Quinolines; Reproducibility of Results; Sensitivity and Specificity; Spectrophotometry, Ultraviolet; Young Adult | 2010 |
Determination of moxifloxacin in dried blood spots using LC-MS/MS and the impact of the hematocrit and blood volume.
Topics: Antitubercular Agents; Aza Compounds; Blood Specimen Collection; Blood Volume; Chromatography, Liquid; Drug Monitoring; Drug Stability; Fluoroquinolones; Hematocrit; Humans; Linear Models; Moxifloxacin; Quinolines; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry; Tuberculosis | 2011 |
Simple and rapid liquid chromatography method for determination of moxifloxacin in saliva.
Topics: Aza Compounds; Chromatography, High Pressure Liquid; Female; Fluoroquinolones; Humans; Linear Models; Male; Moxifloxacin; Quinolines; Reproducibility of Results; Saliva; Sensitivity and Specificity | 2011 |
Development and validation of liquid chromatography-mass spectrometric method for simultaneous determination of moxifloxacin and ketorolac in rat plasma: application to pharmacokinetic study.
Topics: Animals; Aza Compounds; Chromatography, High Pressure Liquid; Drug Stability; Fluoroquinolones; Ketorolac; Male; Moxifloxacin; Quinolines; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization | 2012 |
Laboratory diagnosis of Clostridium difficile associated diarrhoea and molecular characterization of clinical isolates.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Aza Compounds; Bacterial Proteins; Bacterial Toxins; Clostridioides difficile; Clostridium Infections; Diarrhea; Drug Resistance, Bacterial; Enterotoxins; Feces; Female; Fluoroquinolones; Genes, Bacterial; Glutamate Dehydrogenase; Humans; Immunoenzyme Techniques; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Prevalence; Quinolines; Ribotyping; Sensitivity and Specificity; Young Adult | 2012 |
Activity of moxifloxacin in combination with vancomycin or teicoplanin against Staphylococcus aureus isolated from device-associated infections unresponsive to glycopeptide therapy.
Topics: Anti-Infective Agents; Aza Compounds; Catheterization; Device Removal; Drug Interactions; Drug Resistance, Multiple, Bacterial; Female; Fluoroquinolones; Glycopeptides; Humans; Italy; Male; Methicillin Resistance; Microbial Sensitivity Tests; Moxifloxacin; Quinolines; Risk Assessment; Sensitivity and Specificity; Staphylococcal Infections; Staphylococcus aureus; Teicoplanin; Treatment Failure; Vancomycin; Vancomycin Resistance | 2003 |
Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis.
Topics: Analysis of Variance; Animals; Antitubercular Agents; Aza Compounds; Biological Availability; Culture Media; Disease Models, Animal; Drug Therapy, Combination; Female; Fluoroquinolones; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Probability; Quinolines; Sensitivity and Specificity; Time Factors; Treatment Outcome | 2004 |
In vitro pharmacodynamic activity of gatifloxacin, gemifloxacin, moxifloxacin and levofloxacin against Streptococcus pneumoniae containing specific mutations in DNA gyrase and topoisomerase IV.
Topics: Analysis of Variance; Aza Compounds; Culture Media; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Naphthyridines; Ofloxacin; Pharmacogenetics; Pneumococcal Infections; Probability; Quinolines; Reference Values; Regression Analysis; Sensitivity and Specificity; Streptococcus pneumoniae | 2003 |
Morphostructural damage and the inhibition of bacterial adhesiveness of Staphylococcus aureus and Moraxella catarrhalis induced by moxifloxacin.
Topics: Aza Compounds; Bacterial Adhesion; Case-Control Studies; Cells, Cultured; Culture Media; Epithelial Cells; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Microscopy, Electron, Scanning; Moraxella catarrhalis; Moxifloxacin; Quinolines; Reference Values; Sampling Studies; Sensitivity and Specificity; Staphylococcus aureus | 2003 |
Susceptibility testing of Singapore strains of Mycoplasma hominis to tetracycline, gatifloxacin, moxifloxacin, ciprofloxacin, clindamycin, and azithromycin by the Etest method.
Topics: Anti-Bacterial Agents; Aza Compounds; Azithromycin; Ciprofloxacin; Clindamycin; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Microbial Sensitivity Tests; Moxifloxacin; Mycoplasma hominis; Quinolines; Sampling Studies; Sensitivity and Specificity; Singapore; Tetracycline | 2004 |
New real-time PCR-based method for in vitro susceptibility testing of Anaplasma phagocytophilum against antimicrobial agents.
Topics: Ampicillin; Anaplasma phagocytophilum; Anti-Bacterial Agents; Aza Compounds; Azithromycin; DNA, Bacterial; DNA, Ribosomal; Doxycycline; Fluoroquinolones; Genes, rRNA; Gentamicins; Ketolides; Microbial Sensitivity Tests; Moxifloxacin; Polymerase Chain Reaction; Quinolines; Reproducibility of Results; RNA, Bacterial; RNA, Ribosomal, 16S; Sensitivity and Specificity | 2004 |
Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis.
Topics: Animals; Antitubercular Agents; Aza Compounds; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluoroquinolones; Mice; Mice, Inbred BALB C; Moxifloxacin; Multivariate Analysis; Quinolines; Random Allocation; Reference Values; Sensitivity and Specificity; Tuberculosis, Pulmonary | 2004 |
Evaluation of moxifloxacin activity in vitro against Mycobacterium tuberculosis, including resistant and multidrug-resistant strains.
Topics: Antibiotics, Antitubercular; Aza Compounds; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Humans; Italy; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Quinolines; Sampling Studies; Sensitivity and Specificity | 2004 |
Susceptibility of Mexican brucella isolates to moxifloxacin, ciprofloxacin and other antimicrobials used in the treatment of human brucellosis.
Topics: Anti-Bacterial Agents; Aza Compounds; Brucella; Brucellosis; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Humans; Mexico; Microbial Sensitivity Tests; Moxifloxacin; Quinolines; Sensitivity and Specificity | 2004 |
Enantiomeric purity assay of moxifloxacin hydrochloride by capillary electrophoresis.
Topics: Aza Compounds; Electrophoresis, Capillary; Fluoroquinolones; Moxifloxacin; Quinolines; Reproducibility of Results; Sensitivity and Specificity; Stereoisomerism | 2005 |
In vitro selection of resistance to clarithromycin in Streptococcus pneumoniae clinical isolates.
Topics: Amoxicillin; Aza Compounds; Azithromycin; Clarithromycin; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines; Sampling Studies; Sensitivity and Specificity; Streptococcus pneumoniae | 2005 |
In vitro activity of fluoroquinolones against Mycobacterium tuberculosis.
Topics: Aza Compounds; Ciprofloxacin; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Quinolines; Quinolones; Sampling Studies; Sensitivity and Specificity | 2005 |
Influence of human ascitic fluid on the in vitro antibacterial activity of moxifloxacin.
Topics: Ascitic Fluid; Aza Compounds; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; In Vitro Techniques; Microbial Sensitivity Tests; Moxifloxacin; Probability; Quinolines; Sampling Studies; Sensitivity and Specificity; Statistics, Nonparametric | 2005 |
Determination of the newer quinolones levofloxacin and moxifloxacin in plasma by high-performance liquid chromatography with fluorescence detection.
Topics: Anti-Bacterial Agents; Aza Compounds; Chromatography, High Pressure Liquid; Fluoroquinolones; Levofloxacin; Moxifloxacin; Ofloxacin; Quinolines; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Fluorescence | 2006 |
Optimization and validation of the direct HPLC method for the determination of moxifloxacin in plasma.
Topics: Anti-Bacterial Agents; Aza Compounds; Calibration; Chromatography, High Pressure Liquid; Fluoroquinolones; Humans; Moxifloxacin; Quinolines; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Fluorescence | 2006 |
Validated spectrophotometric methods for the estimation of moxifloxacin in bulk and pharmaceutical formulations.
Topics: Anti-Bacterial Agents; Aza Compounds; Dosage Forms; Drug Compounding; Fluoroquinolones; Hydrogen-Ion Concentration; Moxifloxacin; Quinolines; Sensitivity and Specificity; Spectrophotometry, Ultraviolet | 2007 |
Application of a validated stability-indicating densitometric thin-layer chromatographic method to stress degradation studies on moxifloxacin.
Topics: Aza Compounds; Calibration; Chromatography, Thin Layer; Densitometry; Drug Stability; Fluoroquinolones; Hydrogen-Ion Concentration; Kinetics; Moxifloxacin; Quinolines; Reproducibility of Results; Sensitivity and Specificity | 2007 |
BAY 12-8039, a novel fluoroquinolone. Activity against important respiratory tract pathogens.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; beta-Lactamases; Fluoroquinolones; Haemophilus influenzae; Humans; Microbial Sensitivity Tests; Moraxella catarrhalis; Moxifloxacin; Quinolines; Respiratory Tract Infections; Sensitivity and Specificity; Species Specificity | 1998 |
Capillary electrophoresis with laser-induced fluorescence: a routine method to determine moxifloxacin in human body fluids in very small sample volumes.
Topics: Anti-Infective Agents; Aza Compounds; Body Fluids; Chromatography, High Pressure Liquid; Electrophoresis, Capillary; Fluorescence; Fluoroquinolones; Humans; Lasers; Male; Microchemistry; Microdialysis; Moxifloxacin; Quality Control; Quinolines; Sensitivity and Specificity; Spectrophotometry | 1998 |
Determination of moxifloxacin (BAY 12-8039) in plasma and lung tissue by high-performance liquid chromatography with ultraviolet detection using a fully automated extraction method with a new polymeric cartridge.
Topics: 4-Quinolones; Anti-Infective Agents; Aza Compounds; Calibration; Chromatography, High Pressure Liquid; Fluoroquinolones; Humans; Lung; Moxifloxacin; Quinolines; Reproducibility of Results; Sensitivity and Specificity; Spectrophotometry, Ultraviolet | 2000 |
Capillary electrophoresis with laser-induced fluorescence in clinical drug development routine application and future aspects.
Topics: Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Drug Design; Electrophoresis, Capillary; Fluoroquinolones; Lasers; Moxifloxacin; Quinolines; Sensitivity and Specificity; Spectrometry, Fluorescence | 2000 |
Ciprofloxacin- and methicillin-resistant staphylococcus aureus susceptible to moxifloxacin, levofloxacin, teicoplanin, vancomycin and linezolid.
Topics: Acetamides; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Base Sequence; Ciprofloxacin; Drug Resistance, Multiple; Fluoroquinolones; Humans; Levofloxacin; Linezolid; Methicillin Resistance; Microbial Sensitivity Tests; Molecular Sequence Data; Moxifloxacin; Ofloxacin; Oxazolidinones; Polymerase Chain Reaction; Quinolines; Sensitivity and Specificity; Staphylococcus aureus; Teicoplanin; Vancomycin | 2001 |
E test susceptibility testing of nosocomial Clostridium difficile isolates against metronidazole, vancomycin, fusidic acid and the novel agents moxifloxacin, gatifloxacin, and linezolid.
Topics: Acetamides; Anti-Infective Agents; Aza Compounds; Clostridioides difficile; Clostridium Infections; Cross Infection; Diarrhea; Fluoroquinolones; Fusidic Acid; Gatifloxacin; Humans; Linezolid; Metronidazole; Microbial Sensitivity Tests; Moxifloxacin; Oxazolidinones; Quinolines; Sensitivity and Specificity; Vancomycin | 2002 |